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Until recently, innovation in healthcare was mainly achieved through the development of
new drugs, therapies, and medical devices by big pharma and medtech companies;
however, the innovative potential for this field is much broader. The patients and
caregivers’ role in healthcare is often associated with disease management, demand
for their own illness data, and its exchange with other patients. However, the patients
and caregivers’ capacity to innovate to cope with limitations associated with their
health condition is a growing phenomenon and starting to be supported by healthcare
stakeholders to achieve a truly patient-centric system. Our previous research has shown
that these uncommon innovators can develop a wide range of solutions, from simple
adaptations and products to highly technological biomedical devices. In this paper,
we present novel solutions developed by rheumatic patients, their caregivers, and
collaborators, published on the “Patient Innovation” platform (https://patient-innovation.
com/), with a focus on the innovator profile, the need that triggers the innovative
process, the type of motivation behind the product, and the products developed. The
most significant needs that motivate innovation are the will to increase the level of
independence (71%) and to be able to perform daily routine activities (65%). In over 80%
of cases, the fact that the market does not fully fulfill the needs felt during daily activities
is the main motivation to innovate. It is thus concluded that there is room for innovation
in rheumatic diseases with solutions developed by patients and informal caregivers that
intend to solve needs that the healthcare market is not covering.
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INTRODUCTION
Rheumatic diseases are in the group of diseases recognized earliest in the world (1), and although
the most common rheumatic diseases present a high prevalence in the elderly population,
rheumatic diseases affect people of all ages and currently have a great impact on patients’ daily
living as well as on society, as it is commonly reflected in high economic costs through a great
consumption of healthcare and social resources.
Despite the critical importance of the healthcare sector for the economy and society, where
average health spending reached 8.8% of gross domestic product (GDP) across the Organization
for Economic Co-operation and Development (OECD) (2), current healthcare provision does not
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always meet patient’s real and daily needs. To solve this, some
patients and informal caregivers do not wait for a solution to
come up in the market, and thus start developing innovative
solutions to overcome limitations associated with the health
condition that they face (3, 4). Von Hippel started to introduce
the concept of user innovation as individuals or firms who
expect to directly benefit from a product that they have created
(5, 6); this concept differs from producer innovators—firms
or individuals who develop novel products to benefit from
selling it as a better or new product or service. Thus, when
translating the concept of user innovation to the healthcare
domain, patient innovators are citizens who develop useful and
innovative solutions to cope with their health disorders. These
patient innovations range from simple products for everyday use
to unknown therapies and high-tech solutions (7). These findings
suggested that patients and informal caregivers worldwide may
contribute with a high number of innovative solutions with a
valid need-based motivation and, if shared and adopted, can
improve not only their quality of life but also the life of others
with similar health conditions (8). This was the motivation
for the creation of the website www.patient-innovation.com,
a non-profit international, multilingual, and open platform
which currently presents over 1,500 solutions developed by
patients, informal caregivers, and collaborators which have been
submitted or collected, medically validated, and shared.
In this paper, it is our intention to present and describe
relevant innovative solutions developed by rheumatic patients,
their informal caregivers, and collaborators, who decided to solve
some of their everyday needs—originated by the health condition
that they face—but could not find any solution in the market.
METHODS
In order to analyze innovative solutions developed by patients
and informal caregivers, the ‘Patient Innovation’ platform
(www.patient-innovation.com) was used as its presents itself as
a centralized inventory of patient-developed solutions.
The ‘Patient Innovation’ platform provides the opportunity to
patients and caregivers to actively engage in sharing solutions
within the Patient Innovation community. In order to share
a novel solution, the user must register on the website (the
connection to Patient Innovation is always encrypted and
personal data is only stored in high security data centers
located in the European Union) and, once logged in, the
user can write down his/her solutions for dealing with a
condition in his/her daily life (information required: solution
title, description, about the innovator, and optional images and
videos). Before being published, the Patient Innovation’s medical
team evaluates and validates (or not) the submitted solutions,
by only approving the ones that are not drugs, chemicals,
intake/topical substances, invasive devices, or other visibly and
intrinsically dangerous proposals. Once these are online, they are
available to everyone who may be interested, or can benefit from
the published solutions.
The medically validated and published solutions in the
‘Patient Innovation’ platform were screened, and solutions that
showed features to be possible solutions for rheumatologic
diseases were selected. In a first stage analysis, disease-based
motivation was screened and rheumatology-based solutions were
distinguished from solutions that cover rheumatologic patients’
needs/symptoms but were based on other medical conditions.
Through the innovation description and information available
about the innovator, the type of innovator (patient, caregiver, or
collaborator), sex, country, product category (the exact role/goal
of the solution developed, divided into the following categories:
activities of daily living, pain/therapy, hobbies, and movement),
motivation (why the innovators had to develop a novel solution
to cope with a limitation/need related with the health condition
that they face, divided into the following categories: “the products
in the market were not useful to satisfy the need,” “there was
not any alternative in the market,” “cost of the alternatives in
the market,” and “other”) and need to innovate (the need that
made the patient, caregiver, or collaborator to innovate and create
a novel product, divided into the following categories: “to be
able to perform personal hygiene tasks,” “to be able to perform
a daily routine activity,” “to increase the level of independency,”
“to be able to move,” “to reduce pain,” “to replace a lost function,”
“to improve therapy,” and “other”) were studied. The criteria
used for categorization was developed by the authors based
on the information available in the solutions description fields
(solution title, description, about the innovator, optional images,
and videos) posted on the ‘Patient Innovation’ platform.
RESULTS
The ‘Patient Innovation’ platform presented 1,399 medically
screened and published solutions when consulted on July 8th
2020 for the purpose of this research work. From those, 101
published innovations showed features that marked them as
possible solutions for rheumatologic patients; most of those
solutions were developed for activities of daily living (54%),
whereas for hobbies (24%), pain/therapy (15%), and movement
(9%) are other significant types of products described in
the platform.
Thirty-four percent (n = 34, Table 1) of those solutions
were developed as a response to rheumatologic-based needs
by patients, informal caregivers, and collaborators who face
difficulties associated with this disease category. The great
majority of rheumatologic-based solutions (82%) were developed
in the same proportion by patients (those who develop solutions
for themselves) and informal caregivers (those who develop
solutions for loved ones and/or family); eighteen percent (n
= 6) of the solutions were developed by collaborators (those
who develop solutions for someone out of his/her family/friends
circle). Fifty-four percent (n = 19) of those solutions were
developed by men (46% by women) and by citizens from
countries of five continents (e.g., USA, Portugal, China, Australia,
and Kenya).
When analyzing the need behind the innovation process
for the rheumatologic-based solutions (Figure 1), the most
significant ones rely on efforts to increase the level of
independency (71%) and to be able to perform a daily routine
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TABLE 1 | Innovative solutions to cope with rheumatic diseases limitations








Hair dryer adaptation for stiff
upper limbs1
Patient Portugal Fibromyalgia




hot-cold therapy to reduce
pain3
Canada Arthritis
ViEx, a string-based device to
reduce hand joints pain4
USA Rheumatoid
arthritis




Food cutting board and knives
to overcome poor hand grip6
New Zealand Rheumatoid
Arthritis
Tool to help with gardening
without having to bend down7
Belgium Arthritis
Adapted transport container
for disabled people scooters8
Belgium Ehlers-Danlos
Syndrome
Nose-pad, a device to work in
a computer/tablet using nose
and lips9
Sweden Arthritis
Gehrad, a walking aid device10 Germany Osteoarthritis




Sandi Gloves, an easier way to
sand12
Australia Arthritis





Fashionable walking aids14 UK Fibromyalgia
Adaptor for car key turning aid
to avoid wrist twisting motion15
Caregiver USA Arthritis
Accessible zipper pull16 USA Arthritis
Assistive door locker17 USA Arthritis
Blanket support to avoid
overweighting joints and still
not get cold18
Portugal Arthritis
Light intensity regulator for car
traveling 19
Portugal Arthritis
Exoskeleton glove to enhance
hand movements20
Greece Arthritis
Wheelchair tank to ease beach
and countryside visits21
UK Arthritis
Egg collector to avoid having
to bend over22
Belgium Myopathy
Stair-climbing wheelchair23 China Arthritis




Stair-climbing booster25 China Arthritis
Toothpaste squeezer for
people with poor grip26
USA Arthritis











Swachchta Suvidha Brush, a
simple slip-on floor cleaner28
India Spondylosis,
Arthritis
Book page turning device29 Collaborator USA Arthritis
Kitchen safety handle for




Obi, a robotic device for
autonomous feeding31
USA Arthrogryposis








Finger support to ease finger
deformities34
USA Arthritis
Patient Innovation platform location (https://patient-innovation.com/xxxx/zzzz):
1/node/502, 2/post/654, 3/post/920, 4/post/1203, 5/post/1234, 6/post/1345,
7/post/1365, 8/post/1372, 9/post/1376, 10/post/1642, 11/post/1648, 12/post/1944,
13/post/2416, 14/post/2473, 15/post/587, 16/post/669, 17/post/670, 18/post/880,
19/post/881, 20/post/1204, 21/post/1266, 22/post/1362, 23/post/1843, 24/post/1845,
25/post/1849, 26/post/1901, 27/post/2088, 28/post/2355, 29/post/861, 30/post/1304,
31/post/1537, 32/post/2022, 33/post/2039, 34/post/2209.
activity (65%). Also, pain reduction (24%), replacing a lost
function (12%), and mobility (12%) are other relevant needs
found in the innovations analyzed.
Following the World Health Organization’s definition for
medical device (9), 32% of the solutions developed as a response
to rheumatologic-based needs under analysis are framed as Class
I medical devices (10), which meets the amount of pain reduction
and replace a lost function as described above; still, 68% of the
analyzed solutions are not framed as medical devices. However,
only 15% of these rheumatologic-based solutions are approved by
regulatory authorities and are currently being commercialized.
Consequently, the type of products developed by these
uncommon innovators mainly rely on activities of daily living
(41%), pain/therapy (24%), movement (18%), and hobbies (18%).
These innovators found as their main motivation to innovate the
fact that the products in the market did not fully meet a need they
had (82%). Furthermore, the cost of alternative products (27%)
and the inexistence of useful alternatives (9%) available in the
market are also importantmotivations to these innovators to start
developing novel solutions to cope with limitations that they face
every day.
DISCUSSION
Although “innovation” is a broad term and it can be applicable in
different disease’s aspects, we can highlight that in the recent years
“innovation” in rheumatology has widely expanded in digital
health, namely through electronic health records, virtual visits,
wearable technologies, and digital therapeutics which improve
access, outcomes, adherence, and research (11, 12) or new
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FIGURE 1 | Need behind the innovation process of rheumatologic-based innovators.
therapeutic production approaches such as biosimilars (13). Still,
this paper intends to expose that there is still some room for
innovation through solutions developed by patients and informal
caregivers who intend to solve needs that the healthcare market
is not yet covering. To do that, the authors have analyzed 34
rheumatologic-based solutions published on Patient Innovation’s
database, 14 developed by patients and 14 by informal caregivers,
which reinforces that one major source of innovation are the
needs that these citizens feel in their daily lives. The fact that 54%
of those solutions were developed by men (46% by women) and
by citizens from countries of five continents (e.g., USA, Portugal,
China, Australia, and Kenya) reflects the patient innovation
process to be as global and diverse as the medical diseases
themselves. The products analyzed vary from simple devices
(e.g., food cutting board and knives to overcome poor hand
grip) to high-tech solutions (e.g., exoskeleton glove to enhance
hand movements).
Thirty-two percent of the solutions developed under analysis
are framed as Class I medical devices; however, only 15%
are approved by regulatory authorities and are currently being
commercialized, as most of the solutions here described were
developed to solve a daily life need felt by patients and informal
caregivers and were not manufactured on a large scale for
commercialization (at least at the analysis moment). This is
a common approach for patient innovators, as this kind of
uncommon inventors have only developed their novel solutions
because they have a validated need that motivated them to
innovate, and thus their main goal was to fulfill that need, not
to profit from it. Still, there has been an increasing number of
patients and informal caregivers who have been establishing their
own solutions in the market as an effective way to distribute their
solutions to others with similar needs (14, 15).
The authors would like to highlight the potential of
platforms such as ‘Patient Innovation’ and other information
and communication technologies to promote an easy interaction
between common citizens and healthcare professionals. Mainly,
healthcare professionals and other stakeholders can use these
resources to learn more about patients’ real needs and the
solutions that they have developed to cope with them, as well
as to start including patients as consultants and their innovation
process into the producer innovation processes. As innovation
by patients and caregivers is still a new topic that has only
started to be explored in recent years, it is important that
healthcare industry representatives increase their awareness of
this phenomenon and support this innovation process to achieve
a more effective and cheaper product development process.
Although this work only shows a brief sample of novel
solutions developed by common citizens for needs associated
with rheumatic diseases, as the authors are sure that many more
solutions exist developed by these uncommon inventors than
the ones published in ‘Patient Innovation’ platform, it is thus
concluded that solutions developed by patients and informal
caregivers can significantly contribute to rheumatic diseases
innovations as it aims to solve needs that the healthcare market is
not yet covering.
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